Search Results for: TSC22D1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
SETDB1 SET domain bifurcated histone lysine methyltransferase 1
  • PKMTs methylate histone lysines
SP110 SP110 nuclear body protein
SPACA9 sperm acrosome associated 9
SPRED1 sprouty related EVH1 domain containing 1
  • Regulation of RAS by GAPs
  • FGFRL1 modulation of FGFR1 signaling
  • RAS signaling downstream of NF1 loss-of-function variants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
TAF5L TATA-box binding protein associated factor 5 like
  • HATs acetylate histones
TGFBR1 transforming growth factor beta receptor 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
TLE1 TLE family member 1, transcriptional corepressor
  • Formation of the beta-catenin:TCF transactivating complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Deactivation of the beta-catenin transactivating complex
  • Repression of WNT target genes
  • Repression of WNT target genes
TP53 tumor protein p53
  • Activation of NOXA and translocation to mitochondria
  • Activation of PUMA and translocation to mitochondria
  • Pre-NOTCH Transcription and Translation
  • Oxidative Stress Induced Senescence
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
  • Oncogene Induced Senescence
  • DNA Damage/Telomere Stress Induced Senescence
  • SUMOylation of transcription factors
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Association of TriC/CCT with target proteins during biosynthesis
  • TP53 Regulates Metabolic Genes
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 Regulates Transcription of DNA Repair Genes
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Expression
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • G2/M DNA damage checkpoint
  • G2/M Checkpoints
  • Stabilization of p53
  • Transcriptional activation of cell cycle inhibitor p21
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Transcriptional Regulation by VENTX
  • RUNX3 regulates CDKN1A transcription
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Factors involved in megakaryocyte development and platelet production
  • Acetylsalicylic acid
  • Zinc
  • Triethyl phosphate
  • AZD 3355
  • 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Osteosarcoma
  • Adrenal carcinoma
  • Thyroid cancer
  • Breast cancer
  • Basal cell carcinoma
  • Malignant melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Malignant pleural mesothelioma
  • Non-small cell lung cancer
  • Esophageal cancer
  • Oral cancer
  • Multiple myeloma
  • Small cell lung cancer
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
  • Glioma
  • Squamous cell carcinoma
  • Kaposi's sarcoma
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Cancer of the anal canal
  • Hepatocellular carcinoma
  • Choriocarcinoma
  • Vulvar cancer
  • Choroid plexus papilloma
  • Burkitt lymphoma
  • Adult T-cell leukemia
  • Hairy-cell leukemia
  • Bladder cancer
  • Chronic lymphocytic leukemia (CLL)
  • Penile cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Colorectal cancer
  • Laryngeal cancer
  • Chronic myeloid leukemia (CML)
TSC22D4 TSC22 domain family member 4
UBE2D1 ubiquitin conjugating enzyme E2 D1
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • TICAM1, RIP1-mediated IKK complex recruitment
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Signaling by BMP
  • Downstream TCR signaling
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • FCERI mediated NF-kB activation
  • CLEC7A (Dectin-1) signaling
  • Ovarian tumor domain proteases
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Synthesis of active ubiquitin: roles of E1 and E2 enzymes
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Neddylation
  • Peroxisomal protein import
  • Negative regulators of DDX58/IFIH1 signaling
  • IKK complex recruitment mediated by RIP1
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
UNC119 unc-119 lipid binding chaperone
VIM vimentin
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Striated Muscle Contraction
  • Interleukin-4 and Interleukin-13 signaling
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Aggrephagy
  • Artenimol
  • Phenethyl Isothiocyanate
WDR73 WD repeat domain 73
WIZ WIZ zinc finger
WNK1 WNK lysine deficient protein kinase 1
  • Stimuli-sensing channels
  • Hyperkalemic distal renal tubular acidosis (RTA type 4), including the following two diseases: Pseudohypoaldosteronism type I (PHA1); Pseudohypoaldosteronism type II (Gordon's syndrome)
ZC3HC1 zinc finger C3HC-type containing 1

Page 3 out of 3 pages